EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3

Ensembl ID : ENSDLEG00000007078
Gene Symbol: GABRB3
3 Cross references
256 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSDLEG00000006644
Gene Symbol: GABRD
3 Cross references
194 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Epsilon

Ensembl ID : ENSDLEG00000000191
Gene Symbol: GABRE
3 Cross references
108 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSDLEG00000012390
Gene Symbol: GABRG1
3 Cross references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSDLEG00000000135
Gene Symbol: GABRG2
3 Cross references
206 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSDLEG00000007042
Gene Symbol: GABRG3
1 Cross references
257 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Pi

Ensembl ID : ENSDLEG00000011916
Gene Symbol: GABRP
1 Cross references
125 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Theta

Ensembl ID : ENSDLEG00000000048
Gene Symbol: GABRQ
3 Cross references
86 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSDLEG00000016804
Gene Symbol: GABBR1
3 Cross references
267 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSDLEG00000012398
Gene Symbol: GABBR2
3 Cross references
208 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSDLEG00000000221
Gene Symbol: GIPR
1 Cross references
93 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSDLEG00000010543
Gene Symbol: GLP1R
3 Cross references
133 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).